News headlines about Insulet (NASDAQ:PODD) have been trending somewhat positive recently, according to Accern Sentiment Analysis. Accern scores the sentiment of news coverage by reviewing more than 20 million news and blog sources in real time. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Insulet earned a news sentiment score of 0.13 on Accern’s scale. Accern also gave headlines about the medical instruments supplier an impact score of 45.8994237606653 out of 100, indicating that recent news coverage is somewhat unlikely to have an effect on the company’s share price in the next few days.
Here are some of the headlines that may have impacted Accern’s rankings:
- Does Insulet Corporation’s (NASDAQ:PODD) Past Performance Indicate A Stronger Future? (finance.yahoo.com)
- $125.25 Million in Sales Expected for Insulet Co. (PODD) This Quarter (americanbankingnews.com)
- NEWS: Medicare Allows Coverage of OmniPod and New Abbott FreeStyle Libre! (healthline.com)
- Ascensia Diabetes Care Expands Strategic Alliance with Insulet Corporation by … (prnewswire.com)
PODD has been the topic of several recent analyst reports. Jefferies Group increased their target price on Insulet from $58.00 to $67.00 and gave the company a “buy” rating in a research note on Friday, November 3rd. Wedbush restated a “buy” rating and issued a $65.00 price target (up from $60.00) on shares of Insulet in a research note on Tuesday, October 10th. Zacks Investment Research downgraded Insulet from a “buy” rating to a “hold” rating in a research note on Saturday, November 11th. Barclays restated a “buy” rating and issued a $78.00 price target on shares of Insulet in a research note on Wednesday, December 13th. Finally, BidaskClub downgraded Insulet from a “buy” rating to a “hold” rating in a research note on Saturday, December 2nd. One analyst has rated the stock with a sell rating, seven have given a hold rating and twelve have given a buy rating to the company’s stock. The company has an average rating of “Buy” and an average target price of $62.53.
Insulet (NASDAQ:PODD) last posted its quarterly earnings results on Thursday, November 2nd. The medical instruments supplier reported ($0.04) EPS for the quarter, beating the Zacks’ consensus estimate of ($0.10) by $0.06. The business had revenue of $121.80 million for the quarter, compared to analysts’ expectations of $114.02 million. Insulet had a negative return on equity of 43.85% and a negative net margin of 6.66%. The business’s quarterly revenue was up 28.4% on a year-over-year basis. During the same period last year, the firm earned ($0.05) earnings per share. research analysts forecast that Insulet will post -0.43 EPS for the current year.
In other Insulet news, Director James C. Mullen purchased 2,500 shares of the firm’s stock in a transaction on Monday, November 13th. The shares were acquired at an average cost of $67.45 per share, with a total value of $168,625.00. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. 2.60% of the stock is owned by company insiders.
ILLEGAL ACTIVITY WARNING: “Insulet (PODD) Receiving Somewhat Positive Media Coverage, Study Shows” was originally posted by BBNS and is the property of of BBNS. If you are reading this report on another site, it was stolen and republished in violation of United States & international copyright legislation. The legal version of this report can be viewed at https://baseballnewssource.com/markets/somewhat-favorable-news-coverage-somewhat-unlikely-to-impact-insulet-podd-stock-price/1821626.html.
Insulet Corporation is engaged in the development, manufacturing and sale of the OmniPod Insulin Management System (the OmniPod System), an insulin delivery system for people with insulin-dependent diabetes. The Omnipod System features a self-adhesive disposable tubeless Omnipod device, which is worn on the body for approximately three days at a time and its wireless companion, the handheld Personal Diabetes Manager (PDM).
Receive News & Ratings for Insulet Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Insulet and related companies with MarketBeat.com's FREE daily email newsletter.